Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

LB54640

Generic Name: LB54640

Drug Type: Small Molecule

Overview

LB54640 is orally-administered small molecule agonist of the melanocortin 4 receptor.

Background

LB54640 is orally-administered small molecule agonist of the melanocortin 4 receptor.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Phase 2

Active, not recruiting

Posted: 2023/09/21

Sponsor:Rhythm Pharmaceutica...

ID:NCT06046443

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

Phase 2

Not yet recruiting

Posted: 2023/09/18

Sponsor:

LG Chem

ID:NCT06041841

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Phase 1

Completed

Posted: 2023/09/15

Sponsor:

LG Chem

ID:NCT06040372

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Setmelanotide Receives Orphan Drug Designation in Japan for Hypothalamic Obesity Treatment

2 months ago

Rhythm Pharmaceuticals' setmelanotide has received orphan drug designation from Japan's Ministry of Health for the treatment of acquired hypothalamic obesity, a rare condition affecting an estimated 5,000-8,000 patients in Japan.

FDA Grants Priority Review for Setmelanotide sNDA in Young Children with Rare Genetic Obesity

9 months ago

The FDA has accepted Rhythm Pharmaceuticals' sNDA for setmelanotide, seeking approval for children aged 2-6 with obesity due to Bardet-Biedl syndrome or POMC/LEPR deficiency.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy